Published in J Clin Oncol on September 24, 2012
Colorectal cancer screening and prevention in women. Dig Dis Sci (2015) 1.46
Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol (2013) 0.93
Primary prevention of colorectal cancer: myth or reality? World J Gastroenterol (2014) 0.86
Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol (2015) 0.86
Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med (2014) 0.82
Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids (2014) 0.82
Digoxin use and the risk for colorectal cancer. Pharmacoepidemiol Drug Saf (2014) 0.82
Sexual dimorphism in cancer. Nat Rev Cancer (2016) 0.78
Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats. Cancer Prev Res (Phila) (2013) 0.77
No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women. Menopause (2014) 0.75
Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies. PLoS One (2017) 0.75
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC). Sci Rep (2016) 0.75
Thyroid dysfunction, thyroid hormone replacement and colorectal cancer risk. J Natl Cancer Inst (2015) 0.75
Reproductive factors and risk of colorectal polyps in a colonoscopy-based study in western Washington State. Cancer Causes Control (2017) 0.75
Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study. Br J Cancer (2016) 0.75
CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. Br J Cancer (2016) 0.75
IL-8 Is Involved in Estrogen-Related Receptor α-Regulated Proliferation and Migration of Colorectal Cancer Cells. Dig Dis Sci (2017) 0.75
The influence of hormone therapies on colon and rectal cancer. Eur J Epidemiol (2016) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2001) 3.14
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 3.13
Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med (1999) 2.42
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause (2010) 2.26
How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol (1999) 2.10
Association between cigarette smoking and colorectal cancer in the Women's Health Initiative. J Natl Cancer Inst (2007) 1.94
Delay in treatment of colorectal cancer: multifactorial problem. World J Surg (2003) 1.89
Colorectal cancer prevention. J Clin Oncol (2005) 1.86
Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int J Cancer (1996) 1.66
Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric (2011) 1.47
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2008) 1.42
Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev (2009) 1.29
Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 1.23
The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer (2011) 1.14
Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer (USA). Cancer Causes Control (1999) 1.13
Doctor, what's wrong with me? Factors that delay the diagnosis of colorectal cancer. Patient Educ Couns (2011) 1.11
Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.07
Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer (2011) 1.06
Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes Control (2003) 1.06
Estrogen and progestogen therapy in postmenopausal women. Fertil Steril (2008) 1.05
Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod (2007) 1.04
Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiol (2010) 0.92
Menopausal hormone therapy, hormone receptor status, and lung cancer in women. Semin Oncol (2009) 0.91
Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiol Biomarkers Prev (1995) 0.90
National Osteoporosis Society's Position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. Menopause Int (2011) 0.89
Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev (2009) 0.88
Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2011) 0.88
Guidelines and recommendations on hormone therapy in the menopause. J Midlife Health (2010) 0.87
Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. Cancer Causes Control (2001) 0.86
Chemoprevention of colorectal cancer: a role for ursodeoxycholic acid, folate and hormone replacement treatment? Best Pract Res Clin Gastroenterol (2011) 0.85
Hormone therapy in relation to survival from large bowel cancer. Cancer Causes Control (2008) 0.82
Colorectal cancer screening and prevention in women. Womens Health (Lond Engl) (2011) 0.81
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Smoking and mortality--beyond established causes. N Engl J Med (2015) 5.54
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) (2009) 4.08
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA (2013) 3.40
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies. Biostatistics (2008) 3.09
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med (2011) 3.00
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst (2011) 2.84
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst (2010) 2.82
Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. J Womens Health (Larchmt) (2013) 2.81
Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA (2007) 2.81